Diamyd Medical AB (OSTO:DMYD B) Net Change in Cash : kr196.23 Mil (TTM As of May. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Diamyd Medical AB's Net Change in Cash for the three months ended in May. 2025 was kr215.51 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in May. 2025 was kr196.23 Mil.

Diamyd Medical AB Net Change in Cash Historical Data

The historical data trend for Diamyd Medical AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Net Change in Cash Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Net Change in Cash

Get a 7-Day Free Trial

21.67

81.01

-19.62

7.77

-14.78

Diamyd Medical AB Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25
Net Change in Cash	Get a 7-Day Free Trial															-14.12	-10.27	40.12	-49.13	215.51

Diamyd Medical AB Net Change in Cash Calculation

Diamyd Medical AB's Net Change in Cash for the fiscal year that ended in Aug. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-129.181	+	-27.994	+	142.284	+	0.116
	=	-14.78

Diamyd Medical AB's Net Change in Cash for the quarter that ended in May. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -43.5 + -4.25 + 258.958 + 4.304

= 215.51

Net Change in Cash for the trailing twelve months (TTM) ended in May. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr196.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Diamyd Medical AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Net Change in Cash

Comparable Companies

OSTO:SANION OSTO:XSPRAY OSTO:EGTX OSTO:HNSA OSTO:SYNACT OSTO:IBT B OSTO:GENO XSAT:HAMLET B OSTO:VICO OSTO:FLUO VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX

Traded in Other Exchanges

DYMDF:USA

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines